Neurolixis

Executive Summary

Neurolixis is a French early-stage biopharmaceutical company founded in 2012, specializing in developing novel small molecule drugs for central nervous system (CNS) disorders. The company leverages its deep expertise in serotonin receptor pharmacology to design highly selective and biased agonists targeting unmet medical needs in movement disorders, rare autism spectrum disorders, depression, and pain. With a focus on precision modulation of serotonin receptors, Neurolixis aims to improve efficacy and reduce side effects compared to existing therapies. The company is currently in Phase 2 development for its lead programs, positioning itself in the competitive CNS landscape. While specific financial details and pipeline milestones are limited, Neurolixis's approach addresses significant gaps in CNS therapeutics, particularly in rare diseases with no approved treatments. The company's early-stage status and reliance on serotonin receptor modulation present both scientific potential and execution risks.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead program in autism spectrum disorder30% success
• Q2 2026Announcement of a strategic partnership or licensing deal20% success
• Q3 2026Grant or non-dilutive funding award to support pipeline expansion50% success